Skip to main content

Advertisement

SpringerLink
Log in

The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas

  • Review
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Pituitary adenomas are monoclonal neoplasms that may secrete excessive quantities of their endogenous hormones, or may not be associated with any obvious syndrome, in which case they are known as non-functioning pituitary adenomas. Around 2 % have been said to occur in a familial setting, in the absence of any other tumor, now described as familial isolated pituitary adenomas (FIPA). Some 15–30 % of such families harbor inactivating germ-line mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene, along with 20 % of pediatric seemingly sporadic cases. AIP mutants are referred to as having pituitary adenoma predisposition, and present with early onset, aggressive macroadenomas, most of which secrete somatotropin. Evidence from transfection studies implies that AIP acts as a tumor suppressor; although whether this is mediated through an interaction with the aryl hydrocarbon receptor, phosphodiesterases, or with cell cycle regulators such as survivin or RET remains controversial. However, at present an interaction with the cyclic AMP pathway seems most plausible. Recently, evidence has shown that AIP may act at the cell surface, causing changes in integrin function. The presence of AIP mutations in a significant proportion of FIPA families as well as in apparently sporadic cases, particularly in young patients, suggests a need to screen such patients for AIP mutations to enable better clinical management. However, the absence of AIP mutations in over half of such cases highlights the need to search for further gene mutations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. A.F. Daly, M. Rixhon, C. Adam, A. Dempegioti, M.A. Tichomirowa, A. Beckers, High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91(12), 4769–4775 (2006)

    Article  CAS  PubMed  Google Scholar 

  2. A. Fernandez, N. Karavitaki, J.A. Wass, Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf) 72(3), 377–382 (2010)

    Article  Google Scholar 

  3. S. Ezzat, S.L. Asa, W.T. Couldwell, C.E. Barr, W.E. Dodge, M.L. Vance, I.E. McCutcheon, The prevalence of pituitary adenomas: a systematic review. Cancer 101, 613–619 (2004)

    Article  PubMed  Google Scholar 

  4. A.F. Daly, J.F. Vanbellinghen, S.K. Khoo, M-l Jaffrain-rea, L.A. Naves et al., Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metabol. 92(5), 1891–1896 (2010)

    Article  Google Scholar 

  5. J.W. Cain, D. Miljic, V. Popovic, M. Korbonits, Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma. Expert Rev. Endocrinol. Metab. 5(5), 681–695 (2010)

    Article  CAS  Google Scholar 

  6. S. Igreja, H.S. Chahal, P. King, G.B. Bolger, U. Srirangalingam, L. Guasti et al., Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum. Mutat. 31, 950–960 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. C.A. Leontiou, M. Gueorguiev, J. Van Der Spuy, R. Quinton, F. Lolli, S. Hassan et al., The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metabol. 93(6), 2390–2401 (2008)

    Article  CAS  Google Scholar 

  8. M.A. Tichomirowa, A. Barlier, A.F. Daly, M-l Jaffrain-rea, C. Ronchi et al., High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur. J. Endocrinol. 165(4), 509–515 (2011)

    Article  CAS  PubMed  Google Scholar 

  9. A.F. Daly, M-l Jaffrain-Rea, A. Ciccarelli et al., Clinical Characterization of Familial Isolated Pituitary Adenomas. J. Clin. Endocrinol. Metabol. 91(9), 3316–3323 (2006)

    Article  CAS  Google Scholar 

  10. H.S. Chahal, J.P. Chapple, L.A. Frohman, A.B. Grossman, M. Korbonits, Clinical, genetic and molecular characterisation of patients with familial isolated pituitary adenomas. Trends Endrocrinol. Metab. 21(7), 419–427 (2010)

    Article  CAS  Google Scholar 

  11. P. Benilan, S. Giraud, N. Lahlou et al., Familial acromegaly: a specific clinical entity—further evidence from the genetic study of a three-generation family. Eur. J. Endocrinol. 133, 451–456 (1995)

    Article  Google Scholar 

  12. M.R. Gadelha, T.R. Prezant, K.N. Une et al., Loss of heterozygosity on chromosome 11q13 in two families with acromegaly/gigantism is independent of mutations of the multiple endocrine neoplasia type 1 gene. J. Clin. Endocrinol. Metab. 84, 249–256 (1999)

    CAS  PubMed  Google Scholar 

  13. M.R. Gadelha, K.N. Une, K. Rohde, M. Vaisman, R.D. Kineman, L.A. Frohman, Isolated familial somatotropinomas: establishment of linkage to chromosome 11q13.1–11q13.3 and evidence for a potential second locus at chromosome 2p16–121. J. Clin. Endocrinol. Metab. 85(2), 707–714 (2000)

    CAS  PubMed  Google Scholar 

  14. O. Vierimaa, M. Georgitsi, R. Lehtonen, P. Vahteristo, A. Kokko et al., Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312(5777), 1228–1230 (2006)

    Article  CAS  PubMed  Google Scholar 

  15. F. Martucci, G. Trivellin, M. Korbonits, Familial isolated pituitary adenomas: an emerging clinical entity. J. Endocrinol. Invest. 35(11), 1003–1014 (2012)

    Article  CAS  PubMed  Google Scholar 

  16. G. Occhi, M.L. Jaffrain-Rea, G. Trivellin, N. Albiger, F. Ceccato, E. De Menis, M. Angelini, S. Ferasin, A. Beckers, F mantero, C Scaroni. The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: mutational hot-spot or founder effect? J. Endocrinol. Invest. 33(11), 800–805 (2010)

    Article  CAS  PubMed  Google Scholar 

  17. H.S. Chahal, K. Stals, M. Unterländer, D.J. Balding, M.G. Thomas et al., AIP mutation in pituitary adenomas in the 18th century and today. N. Engl. J. Med. 364(1), 43–50 (2011)

    Article  CAS  PubMed  Google Scholar 

  18. A.F. Daly, M.A. Tichomirowa, P. Petrossians, E. Heliövaara, M-l Jaffrain-rea et al., Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J. Clin. Endocrinol. Metabol. 95(11), 373–383 (2010)

    Article  Google Scholar 

  19. B.M. Arafah, M.P. Nasrallah, Pituitary tumors: pathophysiology, clinical manifestations and management. Endocr. Relat. Cancer 8, 287–305 (2001)

    Article  CAS  PubMed  Google Scholar 

  20. A.F. Daly, M.A. Tichomirowa, A. Beckers, Genetic, molecular and clinical features of familial isolated pituitary adenomas. Horm. Res. 71(2), 116–122 (2009)

    Article  CAS  PubMed  Google Scholar 

  21. L. de Kasuki Jomori Pinho, L. Vieira Neto, L.E. Armondi Wildemberg, E.L. Gasparetto, J. Marcondes, B. de Almeida Nunes, C.M. Takiya, M.R. Gadelha et al., Low aryl hydrocarbon receptor-interacting protein expression is a better marker of invasiveness in somatotropinomas than Ki-67 and p53. Neuroendocrinology 94(1), 39–48 (2011)

    Article  Google Scholar 

  22. L.A. Naves, A.F. Daly, J.F. Vanbellinghen, L.A. Casulari, C. Spilioti, A.V. Magalhaes et al., Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptor-interacting protein gene. Eur. J. Endocrinol. 157, 383–391 (2007)

    Article  CAS  PubMed  Google Scholar 

  23. A. Raitila, H.J. Lehtonen, J. Arola, E. Heliövaara, M. Ahlsten, M. Georgitsi et al., Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. Am. J. Pathol. 177(4), 1969–1976 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. A. Beckers, L.A. Aaltonen, A.F. Daly, A. Karhu, Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr. Rev. 34(2), 239–277 (2013)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. S.K. Khoo, R. Pendek, R. Nickolov, D.C. Luccio-Camelo, T.L. Newton, A. Massie, D. Petillo, J. Menon, D. Cameron, B.T. Teh, S.P. Chan, Genome-wide scan identifies novel modifier loci of acromegalic phenotypes for isolated familial somatotropinoma. Endocr. Relat. Cancer 16(3), 1057–1063 (2009)

    Article  CAS  PubMed  Google Scholar 

  26. B.H. Kang, F. Xia, R. Pop, T. Dohi, M. Socolovsky, D.C. Altieri, Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein. J. Biol. Chem. 286(19), 16758–16767 (2011)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. M. Georgitsi, E. Heliovaara, R. Paschke et al., Large genomic deletions in AIP in pituitary adenoma predisposition. J. Clin. Endocrinol. Metab. 93, 4146–4151 (2008)

    Article  CAS  PubMed  Google Scholar 

  28. L. Cazabat, J. Bouligand, S. Salenave, M. Bernier, S. Gaillard, F. Parker et al., Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. J. Clin. Endocrinol. Metabol. 97(4), 663–670 (2012)

    Article  Google Scholar 

  29. C.A. Stratakis, M.A. Tichomirowa, S. Boikos et al., The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin. Genet. 78, 457–463 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. M. Herincs, S. Owusu-Antwi, H.S. Chahal et al. Prevalence of familial isolated pituitary adenomas (FIPA). Endocr. Abstracts 31[Society for Endocrinology BES 2013], 258 (2013)

  31. L.C. Hernández-Ramírez, P. Gabrovska, J. Dénes et al. Pituitary adenomas due to aryl hydrocarbon receptor interacting protein (AIP) Gene mutations: genotypic–phenotypic characteristics, screening and prospective diagnosis. Endocr. Rev. 34[03_MeetingAbstracts], OR42-5. (2013)

  32. B.C. Lin, R. Sullivan, Y. Lee, S. Moran, E. Glover, C.A. Bradfield, Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. J. Bio. Chem. 282, 35924–35932 (2007)

    Article  CAS  Google Scholar 

  33. H.S. Chahal, G. Trivellin, C.A. Leontiou et al., Somatostatin analogs modulate AIP in somatotroph adenomas: the role of the ZAC1 pathway. J. Clin. Endocrinol. Metab. 97, 1411–1420 (2012)

    Article  Google Scholar 

  34. A. Kazlauskas, L. Poellinger, I. Pongratz, The immunophilin-like protein XAP2 regulates ubiquitination and subcellular localisation of the dioxin receptor. J. Bio. Chem. 275, 41317–41324 (2000)

    Article  CAS  Google Scholar 

  35. Z. Ozfirat, M. Korbonits, AIP gene and familial isolated pituitary adenomas. Mol. Cell. Endocrinol. 326(1), 71–79 (2010)

    Article  CAS  PubMed  Google Scholar 

  36. A.C. Pesatori, A. Baccarelli, D. Consonni, A. Lania, P. Beck-Peccoz et al., Aryl hydrocarbon receptor-interacting protein and pituitary adenomas: a population-based study on subjects exposed to dioxin after the Seveso, Italy, accident. Eur. J. Endocrinol. 159(6), 699–703 (2008)

    Article  CAS  PubMed  Google Scholar 

  37. J.H. Park, D. Mangal, A.J. Frey, R.G. Harvey, I.A. Blair, T.M. Penning, Aryl hydrocarbon receptor facilitates DNA strand breaks and 8-oxo-2′-deoxyguanosine formation by the aldo-keto reductase product benzo[a]pyrene-7,8-dione. J. Bio. Chem. 284, 29725–29734 (2009)

    Article  CAS  Google Scholar 

  38. L. Peng, C.N. Mayhew, M. Schnekenburger, E.S. Knudsen, A. Puga, Repression of Ah receptor and induction of transforming growth factor-beta genes in DEN-induced mouse liver tumors. Toxicology 246, 242–247 (2008)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  39. M.A. Barhoover, J.M. Hall, W.F. Greenlee, R.S. Thomas, Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol. Pharmacol. 77(2), 195–201 (2010)

    Article  CAS  PubMed  Google Scholar 

  40. J.M. Hall, M.A. Barhoover, D. Kazmin, D.P. McDonnell, W.F. Greenlee, R.S. Thomas, Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol. Endocrinol. 24, 359–369 (2010)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. M-l Jaffrain-Rea, M. Angelini, D. Gargano et al., Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr. Relat. Cancer 16, 1029–1043 (2009)

    Article  CAS  Google Scholar 

  42. E. Heliovaara, A. Raitila, V. Launonen et al., The expression of AIP-related molecules in elucidation of cellular pathways in pituitary adenomas. Am. J. Pathol. 175, 2501–2507 (2009)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. G. Trivellin, G. Occhi, N. Albiger et al. AHRR is overexpressed in somatotropinomas. Presented at: XXXIV Giornate Endocrinologiche Pisane. Pisa, Italy, (2010)

  44. C.A. Landis, S.B. Masters, A. Spada, A.M. Pace, H.R. Bourne, L. Vallar, GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340(6236), 692–696 (1989)

    Article  CAS  PubMed  Google Scholar 

  45. G.B. Bolger, A.H. Peden, M.R. Steele, C. MacKenzie, D.G. McEwan, D.A. Wallace, E. Huston, G.S. Baillie, M.D. Houslay, Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2J. Biol. Chem. 278, 33351–33363 (2003)

    Article  CAS  Google Scholar 

  46. B. Oesch-Bartlomowicz, A. Huelster, O. Wiss et al., Aryl hydrocarbon receptor activation by cAMP vs. dioxin: divergent signaling pathways. Proc. Natl. Acad. Sci. USA 102, 9218–9223 (2005)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. R. Formosa, A. Xuereb-Anatasi, J. Vassallo, Aip regulates cAMP signalling and GH secretion in GH3 cells. Endocr. Relat. Cancer 20(4), 495–505 (2013)

    Article  CAS  PubMed  Google Scholar 

  48. S.K. De Oliveira, M. Hoffmeister, S. Gambaryan, W. Muller-Esterl, J.A. Guimaraes, A.P. Smolenski, Phosphodiesterase 2A forms a complex with the co-chaperone XAP2 and regulates nuclear translocation of the aryl hydrocarbon receptor. J. Biol. Chem. 282, 13656–13663 (2007)

    Article  PubMed  Google Scholar 

  49. B.H. Kang, D.C. Altieri, Regulation of survivin stability by the aryl hydrocarbon receptor-interacting protein. J. Bio. Chem. 281, 24721–24727 (2006)

    Article  CAS  Google Scholar 

  50. P. Fortugno, E. Beltrami, J. Plescia et al., Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 100, 13791–13796 (2003)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. C. Canibano, N.L. Rodriguez, C. Saez, S. Tovar, M. Garcia-Lavandeira, M.G. Borrello, A. Vidal et al., The dependence receptor Ret induces apoptosis in somatotrophs through a Pit-1/p53 pathway, preventing tumor growth. EMBO J. 26, 2015–2028 (2007)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. M. Vargiolu, D. Fusco, I. Kurelac et al., The tyrosine kinase receptor RET interacts in vivo with aryl hydrocarbon receptorinteracting protein to alter survivin availability. J. Clin. Endocrinol. Metab. 94, 2571–2578 (2009)

    Article  CAS  PubMed  Google Scholar 

  53. E.D. Aflorei, C. Chen, I. M. McGonnel, R.C. Foweks, A.B. Grossman, N. Tapon, R. Stanewsky, M. Korbonits, Development of novel AIP (aryl hydrocarbon receptor-interacting protein) gene study models using the fruitfly and the zebrafish. 15th International Congress of Endocrinology, Florence, Italy, 5–9 May, (Abstract) (2012)

  54. E.D. Aflorei, C. Chen, B. Klapholz, A.B. Grossman, N. Tapon, N. Brown, R. Stanewsky, M. Korbonits. Aryl hydrocarbon receptor-interacting protein (AIP) homologue in the fruitfly. Austrian Journal of Clinical Endocrinology and Metabolism, 5, 56 (Abstract) (2012)

  55. T. Cuny, M. Pertuit, M. Sahnoun-Fathallah, A. Daly, G. Occhi, M.F. Odou, A. Tabarin, M.L. Nunes, B. Delemer, V. Rohmer, R. Desailloud, V. Kerlan, O. Chabre, J.L. Sadoul, M. Cogne, P. Caron, C. Cortet-Rudelli, A. Lienhardt, L. Raingeard, A.M. Guedj, T. Brue, A. Beckers, G. Weryha, A. Enjalbert, A. Barlier, Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don’t forget MEN1 genetic analysis. Eur. J. Endocrinol. 168(4), 533–541 (2013)

    Article  CAS  PubMed  Google Scholar 

  56. P. Xekouki, K. Pacak, M. Almeida, C.A. Wassif, P. Rustin, M. Nesterova, M. de la Luz Sierra, J. Matro, E. Ball, M. Azevodo, A. Horvath, C. Lyssikatos, M. quezado, N. Patronas, B. Ferrando, B. Pasini, G. Tolis, C.A. Stratakis, Succinate dehydrogenase (SDH) D subunit (SDHD) inactivation in a growth-hormone-producing pituitary tumor: a new association for SDH? J. Clin. Endocrinol. Metab. 97(3), 357–366 (2012)

    Article  Google Scholar 

  57. M.L. Jaffrain-Rea, S. Rotondi, A. Turchi, G. Occhi, A. Barlier, E. Peverelli, L. Rostomyan, C. Defilles, M. Angelini, M.A. Oliva, F. Ceccato, O. Maiorani, A.F. Daly, V. Esposito, F. Buttarelli, D. Figarella-Branger, F. Giangaspero, A. Spada, C. Scaroni, E. Alesse, A. Beckers, Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations. Endocr. Relat. Cancer 20(5), 753–766 (2013)

    Article  CAS  PubMed  Google Scholar 

  58. http://www.fipapatients.org/news/

  59. L. Cazabat, R. Libe, K. Perlemoine, F. Rene-Corail, N. Burnichon, A.P. Gimenez Roqueplo, L. Dupasquier-Fediaevsky, X. Betragna, E. Clauser, P. Chanson, J. Bertherat, M.L. Raffin-Sanson, Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol. 157(1), 1–8 (2007)

    Article  CAS  PubMed  Google Scholar 

  60. M. Georgitsi, A. Raitila, A. Karhu, K. Tuppurainen, M.J. Mäkinen, O. Vierimaa, R. Paschke, W. Saeger, R.B. van der Luijt, T. Sane, M. Robledo, E. De Menis, R.J. Weil, A. Wasik, G. Zielinski, O. Lucewicz, J. Lubinski, V. Launonen, P. Vahteristo, L.A. Aaltonen, Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. PNAS 104(10), 4101–4105 (2007)

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  61. J. Oriola, T. Lucas, I. Halperin, M. Mora, M.J. Perales, C. Alvarez-Escola et al., Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur. J. Endocrinol. 168(1), 9–13 (2012)

    Article  PubMed  Google Scholar 

  62. A. Barlier, J.F. Vanbellinghen, A.F. Daly, M. Silvy, M.L. Jaffrain-Rea, J. Trouillas, G. Tamagno, L. Cazabat, V. Bours, T. Brue, A. Enjalbert, A. Beckers, Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocr. Metab. 92(5), 1952–1955 (2007)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors report that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, Oxford, OX3 7LE, UK

    Catrin Lloyd & Ashley Grossman

  2. Merton College, University of Oxford, Oxford, UK

    Catrin Lloyd

Authors
  1. Catrin Lloyd
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashley Grossman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ashley Grossman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lloyd, C., Grossman, A. The AIP (aryl hydrocarbon receptor-interacting protein) gene and its relation to the pathogenesis of pituitary adenomas. Endocrine 46, 387–396 (2014). https://doi.org/10.1007/s12020-013-0125-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-013-0125-6

Keywords

Search

Navigation